Skip to content

Study · Observational study · n = 1,603 · 2024

5 results

Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes.

Stenberg E, Cao Y, Ottosson J, Hedberg S, Näslund E

Diabetes, obesity & metabolism18 Sept 2024Cited by 2 (Europe PMC)

PMID39295084 (opens in a new tab)DOI10.1111/dom.15952 (opens in a new tab)PepBankPUB-39295084
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes and obesity, mean HbA1c at 2 years was higher after semaglutide (50.7) than after metabolic and bariatric surgery (42.3).

    In plain wordsIn patients with type 2 diabetes and obesity, blood sugar control at 2 years was less good after semaglutide than after weight-loss surgery.

    Peptide
    Semaglutide
    Outcome
    IncreaseMean HbA1c at 2 years
    Study

    n = 1,603

    Comparator
    Metabolic and bariatric surgery
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least 2 yearsAs given in this study (human).

    Measurements

    Mean HbA1c
    50.7
    semaglutide
    Mean HbA1c
    42.3
    surgery

    Source sentences

    Summary
    At 2 years after the intervention, mean glycated haemoglobin was 42.3 ± 11.18 after MBS compared with 50.7 ± 12.48 after semaglutide treatment (p < 0.001)
    2 context sentences
    Summary · context
    Patients treated with either semaglutide for a duration of ≥2 years or MBS in Sweden were identified within the Scandinavian Obesity Surgery Registry and the National Diabetes Registry
    Summary · context
    The study included 606 patients in the surgical group matched to 997 controls who started their treatment from 2018 until 2020.
  2. 02HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes and obesity, complete remission at 2 years was reached by 13.9% on semaglutide versus 63.0% after surgery.

    In plain wordsIn patients with type 2 diabetes and obesity, fewer reached diabetes remission with semaglutide than with weight-loss surgery.

    Peptide
    Semaglutide
    Outcome
    DecreaseComplete diabetes remission at 2 years
    Study

    n = 1,603

    Comparator
    Metabolic and bariatric surgery
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least 2 yearsAs given in this study (human).

    Measurements

    Complete remission
    13.9%
    semaglutide
    Complete remission
    63%
    surgery

    Source sentences

    Summary
    with 382 patients (63.0%) and 139 (13.9%), respectively, reaching complete remission without other treatment than the intervention (p < 0.001)
    2 context sentences
    Summary · context
    Patients treated with either semaglutide for a duration of ≥2 years or MBS in Sweden were identified within the Scandinavian Obesity Surgery Registry and the National Diabetes Registry
    Summary · context
    The study included 606 patients in the surgical group matched to 997 controls who started their treatment from 2018 until 2020.
  3. 03HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes and obesity, mean total weight loss was 5.2% with semaglutide versus 26.4% after surgery.

    In plain wordsIn patients with type 2 diabetes and obesity, weight loss was smaller with semaglutide than with weight-loss surgery.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal weight loss at 2 years
    Study

    n = 1,603

    Comparator
    Metabolic and bariatric surgery
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · at least 2 yearsAs given in this study (human).

    Measurements

    Mean total weight loss
    5.2%
    semaglutide
    Mean total weight loss
    26.4%
    surgery

    Source sentences

    Summary
    Mean total weight loss reached 26.4% ± 8.83% after MBS compared with 5.2% ± 7.87% after semaglutide (p < 0.001).
    2 context sentences
    Summary · context
    Patients treated with either semaglutide for a duration of ≥2 years or MBS in Sweden were identified within the Scandinavian Obesity Surgery Registry and the National Diabetes Registry
    Summary · context
    The study included 606 patients in the surgical group matched to 997 controls who started their treatment from 2018 until 2020.
  4. 04HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes and obesity, both the semaglutide and surgery groups improved in weight.

    In plain wordsIn patients with type 2 diabetes and obesity, weight improved both with semaglutide and with surgery.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight improvement in both groups
    Study

    n = 1,603

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · at least 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Both groups improved in weight and glucometabolic control.
    2 context sentences
    Summary · context
    Patients treated with either semaglutide for a duration of ≥2 years or MBS in Sweden were identified within the Scandinavian Obesity Surgery Registry and the National Diabetes Registry
    Summary · context
    The study included 606 patients in the surgical group matched to 997 controls who started their treatment from 2018 until 2020.
  5. 05HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes and obesity, both the semaglutide and surgery groups improved in glucometabolic control.

    In plain wordsIn patients with type 2 diabetes and obesity, blood sugar control improved both with semaglutide and with surgery.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlucometabolic control improvement in both groups
    Study

    n = 1,603

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Both groups improved in weight and glucometabolic control.
    2 context sentences
    Summary · context
    Patients treated with either semaglutide for a duration of ≥2 years or MBS in Sweden were identified within the Scandinavian Obesity Surgery Registry and the National Diabetes Registry
    Summary · context
    The study included 606 patients in the surgical group matched to 997 controls who started their treatment from 2018 until 2020.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.